Deargen utilizes deep learning algorithms for genome data analysis, biomarker prediction, and drug-target interaction modeling to facilitate the discovery and optimization of new therapeutic molecules. The platform addresses the challenge of developing effective treatments for complex diseases by enabling precision medicine through targeted drug design.
Funding
$16.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The drug discovery process is often slow and expensive, hindering the development of effective treatments for complex diseases. Identifying promising drug candidates and their interactions with specific targets remains a significant bottleneck.
Solution
Deargen offers an AI-driven drug discovery platform, Dr.UG, that accelerates the identification and optimization of therapeutic molecules. The platform leverages deep learning algorithms to analyze genome data, predict relevant biomarkers, and model drug-target interactions. By integrating these capabilities, Deargen facilitates precision medicine through the design of targeted drug candidates, addressing the challenges of undruggable targets and complex disease mechanisms.
Target Audience
Deargen's primary customers are pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and development.
Features
- **DearTRANS:** Genome data analysis using deep learning.
- **WX:** Biomarker prediction for patient stratification and target identification.
- **DearDTI:** AI-powered molecule selection based on predicted drug-target interactions.
- **MolEQ:** Lead optimization using AI to improve drug efficacy and safety profiles.
- Prediction of protein expression levels in breast and ovarian cancer patients by using the Ensemble Technique of Machine Learning.
- Self-Attention Based Molecule Representation for Predicting Drug-Target Interaction